Trump's 100% Pharma Tariff: Who Pays?

The pharmaceutical supply chain's vulnerability has been documented since at least the FDA's 2019 report on foreign API dependence. China manufactures an estimated 80% of the APIs used in US generic drugs; India produces roughly 40% of all finished generic pharmaceuticals sold in the United States, according to a 2024 Congressional Research Service analysis. COVID-19 exposed the risk in real time when Indian export restrictions on certain compounds briefly disrupted hospital supply chains in 2020 — an episode Trump's April 2 executive order cited by name in its preamble.

“Branded drugs manufactured abroad that face the 100% tariff cannot be immediately replaced by domestic production.”

Among the companies announcing investments since April 2: Johnson & Johnson pledged $55 billion in US manufacturing expansion through 2030; Eli Lilly committed $27 billion to a new API production campus in Indiana; Pfizer announced a $25 billion domestic production programme it said would reduce its API imports by 60%. The figures are commitments, not disbursements. Pharmaceutical plants take four to seven years to build and certify, and several analysts have noted that manufacturing commitment announcements have historically overstated eventual capital expenditure by 20% to 40%, according to a Brookings Institution review of comparable industrial policy rounds published January 2026.

The complication the investment narrative buries is near-term price pressure. Branded drugs manufactured abroad that face the 100% tariff cannot be immediately replaced by domestic production. Analysts at SVB Securities estimated in an April 8 note that the tariff, at full implementation, could add between 15% and 30% to the retail price of affected branded medications — including widely used treatments for cancer, autoimmune conditions, and cardiovascular disease.

"This is the pharmaceutical equivalent of shutting the barn door after the horse has been gone for three decades," said Rachel Sachs, Professor of Law at Washington University in St. Louis and a specialist in pharmaceutical regulation, speaking to Reuters on April 9. "The investment timelines mean Americans will pay higher prices for years before a single domestically manufactured pill reaches the pharmacy shelf." The White House trade office countered that price controls under the Inflation Reduction Act's Medicare negotiation provisions would limit consumer exposure — an argument Sachs and other health economists described as applicable to a fraction of the affected drug portfolio.

For insured patients, the most direct near-term impact runs through pharmacy benefit managers — the intermediaries who negotiate drug pricing on behalf of insurers. PBMs typically respond to cost increases by moving branded drugs to higher-cost formulary tiers that shift more expense to patients. Those on Medicare Part D plans have partial protection through the Inflation Reduction Act's $2,000 annual out-of-pocket cap; patients on commercial insurance plans with no equivalent cap are more exposed.

For investors, the tariff reshapes competitive dynamics within the pharmaceutical sector itself. Domestic manufacturers with established US production — including AbbVie, which manufactures Humira in North Chicago, and Amgen, with facilities in Connecticut and California — stand to gain market share from foreign competitors disadvantaged by the tariff structure. Companies with heavy reliance on Indian-manufactured generics face margin compression until they either shift production or pass costs downstream.

The $400 billion in investment commitments announced since April 2 represents a significant industrial policy response. What it does not represent is a guarantee. Pharmaceutical plants take years to build and certify; the tariff takes effect in months. The gap between those two timelines will be filled by higher prices at the pharmacy counter — until the factories are ready.